Development and Validation of a Quantitative Real-Time Polymerase Chain Reaction Classifier for Lung Cancer Prognosis

Introduction: This prospective study aimed to develop a robust and clinically applicable method to identify patients with high-risk early-stage lung cancer and then to validate this method for use in future translational studies. Methods: Three published Affymetrix microarray data sets representing 680 primary tumors were used in the survival-related gene selection procedure using clustering, Cox model, and random survival forest analysis. A final set of 91 genes was selected and tested as a predictor of survival using a quantitative real-time polymerase chain reaction-based assay using an independent cohort of 101 lung adenocarcinomas. Results: The random survival forest model built from 91 genes in the training set predicted patient survival in an independent cohort of 101 lung adenocarcinomas, with a prediction error rate of 26.6%. The mortality risk index was significantly related to survival (Cox model p < 0.00001) and separated all patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 2.82, 4.42). The mortality risk index was also related to survival in stage 1 patients (Cox model p = 0.001), separating patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 3.29, 3.77). Conclusions: The development and validation of this robust quantitative real-time polymerase chain reaction platform allows prediction of patient survival with early-stage lung cancer. Utilization will now allow investigators to evaluate it prospectively by incorporation into new clinical trials with the goal of personalized treatment of patients with lung cancer and improving patient survival.

[1]  L. Ein-Dor,et al.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[4]  Sharon L R Kardia,et al.  Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Marcin Skrzypski,et al.  Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung , 2008, Clinical Cancer Research.

[6]  N. Hayward,et al.  Expression profiling defines a recurrence signature in lung squamous cell carcinoma. , 2006, Carcinogenesis.

[7]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[9]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[10]  A. Bezjak,et al.  Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Beer,et al.  MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. , 2009, Cancer research.

[12]  I. Jurisica,et al.  Prognostic Gene Expression Signature for Squamous Cell Carcinoma of Lung , 2010, Clinical Cancer Research.

[13]  John Van Hoewyk,et al.  A multivariate technique for multiply imputing missing values using a sequence of regression models , 2001 .

[14]  Shuta Tomida,et al.  Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients , 2004, Oncogene.

[15]  Marcin Skrzypski,et al.  A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[16]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[17]  Y. Yatabe,et al.  Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Xianglin Shi,et al.  Constructing Molecular Classifiers for the Accurate Prognosis of Lung Adenocarcinoma , 2006, Clinical Cancer Research.

[19]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[22]  A. Marchetti,et al.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. , 2007, The Journal of clinical investigation.

[23]  Zhifu Sun,et al.  A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer , 2006, PLoS medicine.

[24]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[25]  Hongyu Zhao,et al.  Pathway analysis using random forests with bivariate node-split for survival outcomes , 2010, Bioinform..

[26]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Marcin Skrzypski,et al.  An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[28]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[29]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[30]  Hemant Ishwaran,et al.  Random Survival Forests , 2008, Wiley StatsRef: Statistics Reference Online.

[31]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[32]  N. Hayward,et al.  Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma , 2007, Clinical Cancer Research.

[33]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[34]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[35]  Nam Huh,et al.  Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression , 2008, Clinical Cancer Research.

[36]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[37]  David J Sugarbaker,et al.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[39]  Igor Jurisica,et al.  Prognostic gene signatures for non-small-cell lung cancer , 2009, Proceedings of the National Academy of Sciences.

[40]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Guidel Ines,et al.  Expression profiling — best practices for data generation and interpretation in clinical trials , 2004, Nature Reviews Genetics.

[42]  Zhifu Sun,et al.  Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Ghosh,et al.  Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. , 2007, Cancer research.

[44]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.